Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone. This process requires the synthesis of extracellular matrix ...

The use of isoenzyme-selective phosphodiesterase (PDE) inhibitors is considered a great opportunity to treat various diseases of the human urogenital tract.

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis Results A total of 147 patients were randomly assigned to receive BI 1015550 or placebo.

Discover how phosphodiesterase-4 (PDE-4) inhibitors manage inflammation in people with mild to severe plaque psoriasis.

The rationale for the use of phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension is augmentation of the cyclic guanosine monophosphate pathway.

The FDA warns that amplification by nitroglycerin of the vasodilatory effects of phosphodiesterase inhibitors may result in severe hypotension.

PDE-4 inhibitors are a new type of topical treatment for atopic dermatitis. Learn how these medications work and what to expect if you use them.

Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease ...

WASHINGTON -- Treatment with the first-in-class dual phosphodiesterase 3/4 inhibitor ensifentrine reduced exacerbation rates and improved other key outcomes in patients with chronic obstructive ...

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background ...

Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood ...